Lexeo Therapeutics (LXEO) Non Operating Income (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Non Operating Income of $2.1 million for Q1 2026, down 2.73% sequentially from $2.2 million in Q4 2025, and up 85.99% YoY from $1.1 million in Q1 2025.
Lexeo Therapeutics (LXEO) Non Operating Income (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Non Operating Income for 5 years, with the latest figure at $2.1 million in Q1 2026.
- Quarterly Non Operating Income rose 85.99% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.3 million (up 47.48% YoY) and the FY2025 annual result came in at $9.3 million, up 25.06% from the prior year.
- Non Operating Income retreated to $2.1 million in Q1 2026 per LXEO's latest filing, from $2.2 million in the prior quarter.
- Over five years, Non Operating Income peaked at $4.6 million in Q2 2025 and troughed at $165000.0 in Q3 2023.
- A 5-year average of $1.5 million and a median of $1.4 million in 2025 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income plunged 61.36% in 2023, then jumped 1144.85% in 2024.
- Over 5 years, Non Operating Income stood at $620000.0 in 2022, then advanced by 26.94% to $787000.0 in 2023, then soared by 85.26% to $1.5 million in 2024, then soared by 50.69% to $2.2 million in 2025, then decreased by 2.73% to $2.1 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $2.1 million, $2.2 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | 2.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.15 Mn |
| Mar 31, 2026 | 2.14 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 4.59 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 1.61 Mn |
| Dec 31, 2023 | 787,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Jun 30, 2023 | 534,000.00 |
| Mar 31, 2023 | 633,000.00 |
| Dec 31, 2022 | 620,000.00 |
| Sep 30, 2022 | 427,000.00 |